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Introduction 
Pulmonary hypertension (PH) is said to be present when there is an increase of 
blood pressure in the pulmonary artery, pulmonary vein or pulmonary capillaries. This 
can potentially be a severe disease with markedly decreased exercise tolerance such as 
in heart failure and can cause early mortality.  
It was first identified in 1891 by Ernst von Romberg. 
The 4th World Symposium on Pulmonary Arterial Hypertension was assembled 
in Dana Point in 2008 to modify the previous classification based on new 
understandings of disease mechanisms. The Updated Clinical Classification system 
can be summarised as follows (1): 
 WHO Group I - Pulmonary arterial hypertension (PAH) 
 WHO Group I' - Pulmonary veno-occlusive disease (PVOD) and/ or pulmonary 
capillary haemangiomatosis (PCH) 
 WHO Group II - Pulmonary hypertension owing to left heart disease 
 WHO Group III - Pulmonary hypertension owing to lung disease and/or 
hypoxia 
 WHO Group IV - Chronic thrombo-embolic pulmonary hypertension (CTEPH) 
 WHO Group V - Pulmonary hypertension with unclear multi-factorial 
mechanisms 
During the 5th World Symposium held in Nice, France, in 2013, the consensus 
was reached to maintain the general scheme of previous clinical classifications. (2).  
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Because pulmonary hypertension can be any one of five major types, a series of 
investigations must be performed to distinguish pulmonary arterial hypertension from 
venous, hypoxic, thrombo-embolic, or miscellaneous varieties. These would generally 
include pulmonary function tests; blood tests; electrocardiography (ECG); Plain 
radiographs of the chest (and High Resolution CT scan if interstitial lung disease is 
suspected); and ventilation-perfusion (V/Q) scan to exclude chronic thrombo-embolic 
pulmonary hypertension.  
Normal pulmonary arterial pressure when a person is living at sea level has a 
mean value of 8–20 mm Hg (1066–2666 Pa) at rest. Pulmonary hypertension is said to 
be present when mean pulmonary artery pressure exceeds 25 mm Hg (3300 Pa) at rest. 
A systolic pressure of 40 mm Hg most often implies a mean pressure greater than 25 
mm Hg. Roughly, mPAP = 0.61*sPAP + 2 (3). 
Pulmonary artery catheterisation 
Pulmonary arterial pressure can be calculated indirectly with Echocardiography. 
PAOP (pulmonary artery occlusion pressure) and PVR (pulmonary vascular 
resistance) cannot be measured directly with Echocardiography. Invasive 
measurement of pulmonary artery pressures using a Swan-Ganz catheter is considered 
the gold standard. Diagnosis of PAH, therefore requires right-sided cardiac 
catheterisation. Measurement of pulmonary arterial pressures along with cardiac 
output is far more important in measuring disease severity than pulmonary arterial 
pressure measurements alone. 
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Rationale for the study: 
Right Heart Catheterisation is an invasive technique that requires the use of 
ionizing radiation and has considerable procedure related risks. Hence Pulmonary 
Hypertension is most often diagnosed on echocardiography as it is inexpensive, 
portable, widely available, does not involve ionizing radiation and is non-invasive. 
However, mean Pulmonary Artery Pressure (mPAP) as derived on echocardiography 
is inaccurate and operator dependant. Moreover the prognosis of Pulmonary 
Hypertension depends on various measurements involving the right ventricle, which 
are sub-optimally imaged on Echocardiography owing to its retro-sternal location and 
complex anatomy. Cardiac MRI is excellent for imaging the right ventricle, and 
allows accurate measurements owing to its multi-planar capabilities. It is also a 
validated tool for measuring velocities and flow measurements. From the above 
measurements, it is possible to calculate pulmonary arterial pressures that will help in 
the diagnosis and severity assessment of pulmonary hypertension. Hence, cardiac MRI 
is a versatile and ideal tool for the evaluation of pulmonary hypertension and is widely 
used for this purpose in developed countries.  
To the best of our knowledge, no study has been published in India on the role of 
MRI in pulmonary hypertension. Also, though several studies have already shown 
significant relationship between cardiovascular magnetic resonance (CMR) derived 
measurements with mPAP and PVR in patients with pulmonary hypertension, very 
few retrospective studies and no prospective studies have compared the actual direct 
measurement of right heart pressures with MRI derived values. Therefore this study 
would be one of few of its kind in India. 
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Aims and objectives 
Aim of the study  
To study the correlation between Cardiac Magnetic Resonance Imaging (CMR), 
Echocardiography and, when available, right heart catheterisation in the evaluation of 
pulmonary arterial pressure. 
 
Primary objectives: 
1. To assess the accuracy of CMR when compared to Echocardiography 
and right heart catheterisation (when available), using quantitative parameters, in the 
measurement of pulmonary arterial pressures in patients with clinically suspected HT 
or when suspected on cardiac MRI. 
2. To evaluate the correlation between various parameters in CMR to 
pulmonary arterial pressures measured on Echocardiography and right heart 
catheterisation (when available) using quantitative parameters. 
Secondary objective: 
1. To describe and characterise the various CMR imaging features seen in 
the subset of our subjects with pulmonary hypertension diagnosed on 
Echocardiography qualitatively.   
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Literature review 
Pulmonary Hypertension (PH) is a complex group of disease entities with 
various aetiologies that have a common measurable abnormality that is elevated 
pulmonary arterial pressure. Pulmonary hypertension is said to exist when mean 
pulmonary artery pressure (mPAP) is greater than or equal to 25 mmHg measured at 
cardiac catheterisation (4). However, right heart catheterisation is rarely performed 
solely for the diagnosis of pulmonary hypertension. This is owing to the fact that right 
heart catheterisation is an invasive procedure with significant risk to the patient and 
involves the use of X-rays exposing the patient to harmful radiation.  
Causes of pulmonary hypertension are galore and may be secondary to disease 
affecting the heart, lungs and liver. Strictly speaking, the term pulmonary arterial 
hypertension (PAH) must only be applied to a rare, progressive condition 
characterised by a vasculopathy, although it is often used interchangeably with 
pulmonary hypertension. Mild elevations of pulmonary artery pressure are commonly 
seen in association with several respiratory conditions such as asthma, chronic 
obstructive airway disease and interstitial lung diseases. It is also seen in several 
cardiac diseases such as congenital heart diseases, rheumatic heart disease and even in 
ischaemic heart disease. The 4
th
 world symposium on pulmonary arterial hypertension 
met at Dana Point is 2008 and modified the aetiological classification of Pulmonary 
Hypertension, the main categories of which are stated in the introduction. (1). During 
the 5th World Symposium held in Nice, France, in 2013, the consensus was reached to 
maintain the general scheme of previous clinical classifications. The modified 
classification is as follows: 
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Updated Classification of Pulmonary Hypertension (2) 
1. Pulmonary arterial hypertension 
1′ Pulmonary veno-occlusive disease and/or pulmonary capillary 
hemangiomatosis 
1′′. Persistent pulmonary hypertension of the newborn (PPHN) 
2. Pulmonary hypertension due to left heart disease 
3. Pulmonary hypertension due to lung diseases and/or hypoxia 
4. Chronic thromboembolic pulmonary hypertension (CTEPH) 
5. Pulmonary hypertension with unclear multifactorial mechanisms 
 
Whatever be the underlying cause, the ultimate outcome of patients who develop 
high pressures in their pulmonary arteries is the same. An increase in mPAP and 
pulmonary vascular resistance (PVR) results in right ventricular failure. The initial 
symptoms include dyspnoea and decreased tolerance to exertion. Eventually death 
results, with a median survival after diagnosis in untreated patients of less than 
3 years (5,6). 
 
Right Heart Catheterisation 
Right heart catheterisation (RHC) is the gold standard investigation to determine 
the presence or absence of PH by directly measuring mean pulmonary artery pressure 
(mPAP). In addition, Right Heart Catheterisation also allows measurement of cardiac 
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output (CO) and index (CI, which is the cardiac output in litres per minute per unit 
body surface area), right atrial pressure, mixed venous oxygen saturation and PVR, 
which are used as markers of disease severity. However, although safe in expert hands 
it is an invasive test requiring the patient to have a femoral or jugular puncture and 
intra-vascular catheterisation for accessing the heart chambers and most often requires 
at least one day of hospital stay. Moreover, ionising radiation (X-rays) are used for 
guiding the catheter. (7)The expertise and infra-structure required for performing right 
heart catheterisation are not widely available and even in advanced centres where 
these may be available; it is seldom performed for the diagnosis of Pulmonary 
Hypertension alone. It also adds cost to the patient and the health system. Therefore 
the role of Right heart catheterisation is limited in confirming a diagnosis of PH and is 
often used only in selected cases for assessing the response to treatment.  
 
Echocardiography 
Echocardiography is currently the most commonly used non-invasive test in 
patients with suspected Pulmonary Hypertension. It has definite advantages of being 
inexpensive, widely available and does not involve ionising radiation. It is also fairly 
easy to perform requiring no great equipment or expertise. Mean pulmonary arterial 
pressure (mPAP) on Echocardiogram is calculated as follows: 
The peak velocity of the regurgitant jet at tricuspid valve is first determined. 
This is represented as TV V2max and is representative of the difference in pressures 
between the right atrium and the right ventricle. From this value, the maximum 
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pressure gradient across the tricuspid valve is calculated by squaring this value and 
multiplying it by four.  
 [TV V2 max]2 x4 = TV max PG  
Where TV V2 max stands for maximum velocity of the regurgitant jet at the 
tricuspid valve, TV max PG stands for the maximum pressure gradient across the 
tricuspid valve.  
To this, an arbitrary right atrial pressure of 5 to 7mmHg is added to yield the 
Pulmonary Artery Systolic Pressure (PASP). The latest is to use RA pressure 
estimates from the distensibility and collapsibility of the IVC. From this, the mean 
Pulmonary Artery Pressure may be deduced as follows: 
 mPAP = o.61 x PASP + 2mmHg (3) 
Where mPAP stands for mean pulmonary artery pressure as derived on 
Echocardiogram and PASP stands for pulmonary artery systolic pressure derived on 
Echocardiogram. 
However, Echocardiogram has a number of limitations in the assessment of 
pulmonary pressures and does not perform well for certain aetiologies of PH (8,9). 
Firstly, it is subjective and observer dependant with considerable inter-observer 
variability in measurements. Secondly, the pressures are not directly measured, but 
inferred from other velocity measurements. Thirdly, the right ventricle has a unique 
position behind the sternum and hence is difficult to access and fully assess using 
ultrasound and Doppler signals. Consequently, Echocardiogram significantly over and 
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underestimates invasively measured mPAP(10). Owing to this intrinsic difficulty with 
the pressure measurements, Echocardiography relies on a number of indirect 
indicators of right heart function for corroboration. This includes right ventricular 
volumes such as end diastolic volume and ejection fraction. This s however inaccurate 
because Echocardiogram uses the standard ellipsoid formula for volume calculation 
wheras the shape of the right ventricle is not like and ellipsoid but more like a teapot, 
with the tricuspid valve forming the mouth and the right ventricular outflow tract 
forming the spout. Other indirect indicators such as contraction of the right ventricle 
as quantified by tricuspid annular plane systolic excursion (TAPSE) and septal 
bounce, or bowing of the inter-ventricular septum to the left during systole, though 
useful, are late features in pulmonary hypertension. Consequently, there is increasing 
interest in developing other imaging tools that combine the accuracy of right heart 
catheterisation and the non-invasive ease of Echocardiogram. 
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ESSENTIALS OF MRI AND SPECIFIC FEATURES OF CARDIAC MRI (11) 
 
The nuclear spin phenomenon, T1 and T2 relaxation 
Hydrogen protons in our body associated with fat and water molecules are 
positively charged and spins about its axis acting like tiny magnets, they are randomly 
aligned such that their magnetic fields cancel each other out rather than sum up. In 
MRI examination, the patient is made to lie in a high strength static magnetic field. 
The external magnetic field aligns the spins of the human body, some along the 
direction of the external magnetic field and some in the opposite direction. The 
interaction with the external magnetic field also results in precession of the protons. 
The Larmor equation determines the precessional frequency as f = gyromagnetic ratio 
x main magnetic field. The gyromagnetic ratio is constant and is characteristic for 
each type of nuclei.  
 
The number of spins aligned in the direction of the external magnetic field being 
in excess produces a net magnetization (protons aligned in the direction of the external 
magnetic field minus protons aligned in the direction opposite to the external magnetic 
field). The net magnetization is the resting state, the most favorable situation 
energetically. 
 
Resonance is a property that allows efficient transfer of energy. The net 
magnetization is in a direction parallel to the external magnetic field which is to say it 
is in the longitudinal direction (z direction). A radiofrequency pulse of certain amount 
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of energy is transferred to the protons via the principle of resonance (excitation) such 
that the net magnetization flips to a certain degree rotating away from the longitudinal 
direction. The extent of rotation depends on the strength and duration of the RF pulse. 
The RF pulse strength and duration can be controlled. A 90 degree RF pulse rotates 
the net magnetization into the transverse plane (xy plane, x direction being left- right 
direction, y direction being anterior- posterior direction). A 180 degree RF pulse 
rotates the net magnetization into the - z direction. 
 
After excitation, the spins of the protons return to their resting state. The 
magnetic component along the magnetic field increases and the component along the 
transverse plane or - z direction decreases. T1 relaxation is the gradual recovery of the 
magnetic field component along the net magnetization. T2 relaxation is the gradual 
disappearance of magnetization in the transverse plane (11).  
 
Slice encoding, Phase encoding, frequency encoding 
T1 and T2 relaxation in itself is not enough to construct an image. Spatial 
encoding is a phenomenon whereby magnetic field gradients are applied over a 
volume of interest and an image is constructed. The process is based on the Larmor 
equation. The MR signal is localized by applying gradients that produce controlled 
linear variations in the magnetic field. These gradients are used in slice selection (z), 
phase encoding (y) and frequency encoding (x). 
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Slice selection gradient determines the amount of tissue that is excited by the RF 
pulse. Phase encoding gradient is applied perpendicular to the slice selection gradient 
and after the initial excitation. Frequency encoding is also referred to as the readout 
gradient since MR signal is acquired during the frequency encoding. It is applied to 
the third perpendicular direction to slice the selection and phase the encoding 
gradients. The protons are encoded with different frequency depending on their 
locations.  
 
k-space 
The data obtained from the gradients are stored in a matrix referred to as the k-
space. High signal information is represented in the center and low signal information 
near the periphery, in the edges. Fourier transformation is then used on this 
information in the k-space to reconstruct images.(12) 
 
Spin Echoes and Gradient Echoes  
Spin Echo pulse sequences are now abandoned due to excessive motion artifacts. 
Fast spin Echo / Turbo spin Echo techniques are now employed which can acquire 
image in a single breath hold. They are made of a number of excitation pulses 
separated by a given time interval (TR). A period called the time of Echo (TE) is the 
time between start of an RF pulse and the maximum in signal. It is repeated every TR 
(time of repetition) seconds. The TR is adjusted to coincide with one single R-R 
interval of the patient’s ECG.  
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Steady State Free Precision 
Synchronization with ECG during cardiac MRI is extremely important. SSFP 
sequence is a modification of gradient Echo imaging wherein bright blood images are 
produced that contrasts the background myocardium resulting in a clear delineation 
between them. It is acquired by obtaining a steady state magnetization maintained 
between successive cycles. The high temporal resolution, excellent contrast between 
myocardium and blood within the chambers, and favorable SNR (signal to noise ratio) 
make it good for evaluation of wall motion and volumetric measurement. 
 
 
 
Figure 1 
TRUFISP axial section through the thorax at the level of the main pulmonary artery 
bifurcation. 
The ascending and descending aorta are discerned. 
Both the lungs are visualized and appear unremarkable. 
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Advantages of cardiac MRI  
1. Non invasive investigation with no ionizing radiation being 
involved. 
2. Three dimensional modality making it ideal for assessing 
structures in any plane, especially cardiac chambers. 
3. Now considered the gold standard for volumetric measurements 
of the right heart. 
4. Pulmonary vasculature, lungs and systemic arteries of the chest 
are visualized in the study thereby providing a way to exclude other causes of 
pulmonary hypertension such as pulmonary embolism left sided causes such as 
mitral valve stenosis or various lung conditions such as interstitial lung disease. 
5. The 4D function of cardiac MRI gives accurate information of 
cardiac muscle mass and ventricular volumes and is not limited in visualisation 
nor is it operator dependant as Echocardiography. 
6. Velocity encoded imaging across any plan making flow related 
measurements available from the pulmonary artery. 
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Disadvantages of cardiac MRI  
 
1. Relatively a lengthy examination, taking 30 to 60 minutes of 
machine time for a detailed evaluation. 
2. Patients suffering from claustrophobia, arrhythmias, obesity and 
those who are short of breath and have difficulty lying down may not be able to 
tolerate the examination. 
3.  Registration artifacts occur in the images resulting in blurred 
images in patients with tachycardia and irregular cardiac rhythm. 
4. The technology is not yet widely available and only few 
physicians are trained to perform and interpret these examinations. 
5. Much clinical research is still needed to optimize the diagnostic 
algorithms in cardiac disease. Much awareness amongst cardiologist and 
adequate scientific literature with outcome analysis is required for fully 
comprehending the true value in diagnostic testing in specific clinical 
scenarios. 
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MRI ANATOMY OF THE HEART 
Steady state free precession sequences are best to depict the cardiac anatomy. 
The heart is an intra thoracic organ which rests on the anterior aspect of the diaphragm 
in an oblique position with the lungs on both sides, and its apex in the left hemithorax.  
 
Cardiac structures: 
 
Right atrium (13):  
The right atrium is seen as the right heart border on the frontal chest radiograph. 
Embryologically it develops from the sinus venous and the primitive auricle.  
Characteristic features that distinguish the right atrium are:  
1) The venous component receiving the IVC and SVC in the posterior aspect and 
the coronary sinus in the inferior aspect  
2) The broad based, triangular shaped appendage  
3) A ridge called the crista terminalis which separates the venous part and the 
appendage   
4) Limbus of the fossa ovalis on the septal aspect.  
 
Enlargement of the right atrium displaces the adjacent lung and enlargement of 
the appendage obliterates the retrosternal clear space. 
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Left atrium:  
This forms the upper posterior heart border lying just inferior to the carina and 
anterior in relation to the esophagus. Also forms from the sinus venosus and primitive 
auricle embryologically.  
Characteristic features that distinguish the left atrium are  
1) The venous component receiving the four pulmonary veins at the corner of its 
posterior surface  
2) Long finger like left atrial appendage that overlies the left atrioventricular 
groove and left circumflex coronary artery  
3) Absence of features that suggest right atrial morphology.  
 
When the left atrium is enlarged, it displaces the esophagus towards the posterior 
aspect. It also causes widening of the carina angle. Massive enlargement results in the 
left atrium forming the right heart border on the frontal chest radiograph. Enlargement 
of the appendage displaces the adjacent lung. 
 
Atrial septum:  
The inter-atrial septum separates the left atrium from the right. It is best seen in 
the horizontal / transverse views and longitudinal / four chamber views. It is seen as a 
thin line separating the two atria except at the level of the foramen ovale which is very 
thin and therefore technically difficult to demonstrate, resulting in misinterpretation as 
an atrial septal defect which should be avoided. 
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Figure 2. 
TRUFISP axial image of the thorax at the level of the ventricles showing normal 
anatomy. 
The left ventricular free wall and the interventricular septum are apparent. 
The right ventricular free wall is almost indiscernible, which is normal. The 
moderator band is distinctly seen. 
The pericardium is distinctly made out as a thin hypo-intense line surrounded by 
bright signal from the hyper-intense mediastinal and epicardial fat on both sides. 
Visualized lung fields are unremarkable. 
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Right ventricle (13):  
Pyramidal shaped chamber which rests on the diaphragm and forms the inferior 
and anterior heart border. The right ventricle does not from any part of the apex of the 
heart.  
Characteristic features that distinguish the right ventricles are  
1) Tendinous chord attachment of the tricuspid valve leaflets to the ventricular 
septum  
2) The moderator band (muscular band) containing a continuation of the right 
bundle branch and passing from the ventricular septum to the anterior wall  
3) The tricuspid valve and the pulmonary valves are separated by crista 
supraventricularis which is an in-folding of the roof of the ventricle in the posterior 
margin of the infundibulum. 
 
When compared to the left ventricle, the right ventricular wall is thin and 
measures 3-4 mm at end diastole. Further thinning of the free wall towards the RV 
apex is normal.  
 
Enlargement of the RV chamber results in obliteration of the retrosternal clear 
space and because this space is a small space, the resultant effect of further 
enlargement is that there is displacement of the left ventricle leftward and posteriorly, 
and the apex backward and superiorly. 
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Left ventricle:  
Cone shaped thick walled chamber with its long axis in the left anterior and 
inferior direction. It forms the inferior part of the left heart border, part of the posterior 
heart border and the apex. Its base is formed by the fibrous skeleton of the inlet and 
outlet valves and its apex is the apex of the heart.  
Characteristic features that distinguish the left ventricle are  
1) Fibrous continuity of the inlet and outlet valves due to absence of conus or 
infundibulum  
2) Two papillary muscles – the anterolateral and the posteromedial papillary 
muscles that arise from only the free wall of the ventricle  
3) Absence of features characteristic for right ventricle. 
 
The myocardial thickness in the left ventricle measured in the lateral wall at end 
diastole is 7-8 mm in women and 8-9 mm in men. The apex is thinner and measures 
about 3 mm. Wall thickness is not uniform; it is most pronounced in the longitudinal 
direction with gradual thinning toward the apex and less so in the circumferential 
direction. 
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Ventricular septum:  
The interventricular septum is a thick walled muscular layer that separates the 
right ventricle from the left ventricle. At the sub-aortic location the muscular layer is 
thin and is called the membranous septum.  
The interventricular septum is convex shaped towards the right ventricle which 
is maintained throughout the cardiac cycle. 
 
Valves:  
The mitral valve is always connected to the morphological left ventricle and the 
tricuspid valve to the morphological right ventricle.  
The tricuspid valve is more apically positioned in comparison to the mitral 
valve; this allows differentiation of the ventricular morphology. The tricuspid valve 
has 3 leaflets, septal, inferior and antero-superior leaflets. (12) 
The mitral valve has 2 leaflets, aortic and mural leaflets.  
The semilunar valves attach at the anatomic ventriculo-atrial junction. Both have 
three cusps. 
 
The valve leaflets are thin and fibrous therefore the leaflet morphology, motion 
and abnormal opening and valvular flow patterns may not be optimally assessed.  
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Pericardium:  
The pericardium covers the heart along with the origin of the great vessels. It 
consists of the fibrous part and the serous part. The fibrous part is attached to the 
sternum and the diaphragm. The serous part consists of the visceral layer that is in 
contact with the heart and the pericardial fat and the parietal part which is in contact 
with the inner surface of the fibrous pericardium. The visceral layer reflects at the 
heart and the root of the great vessels onto the inner surface of the fibrous part of the 
pericardium thus becoming continuous with it.  
The pericardial cavity lies between the two layers of the serous part of the 
pericardium and contains about 20-25 ml of serous fluid. This may vary in 
individuals. Two serosal tunnels are present- the transverse sinus, posterior in location 
to the great arteries and anterior to the atria and superior vena cava with its four 
recesses, the superior aortic recess, inferior aortic recess, left pulmonic recess, right 
pulmonic recess, and the oblique sinus, posterior in location to the left atrium. 
 
On magnetic resonance, the normal pericardium is seen as an extremely thin 
hypo-intense curvilinear structure with hyper=intense mediastinal and epicardial fat 
on both sides. It measures 1.2+/- 0.5 mm in diastole and 1.7+/-0.5 mm in systole. 
Thickening of the pericardium the measures more than 4 mm is significant.(14) 
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Planes for MR imaging of the heart 
Scout images: Scout image is taken in the axial plane. Axial images display 
normal anatomy and relationship of the great vessels and cardiac chambers and the 
pericardium depicting the morphology in a plane that is familiar to general radiologist. 
However quantitative measurement of wall thickness, cavity dimensions and 
functional data cannot be assessed. Images can also be taken in any desired orthogonal 
views. 
The heart lies oblique in the thoracic cavity. The true long axis of the heart is 
oriented 45 degrees to the mid-sagittal plane of the thoracic spine. To obtain correct 
inclinations for imaging along the cardiac axes, the following is done: 
 
- Vertical long axis plane: on an axial scout, a plane is chosen that runs through 
the apex of the left ventricle and the middle of the left atrio-ventricular valve which is 
the mitral valve.  
 
- Horizontal long axis / four chamber view: on the vertical long axis, a plane is 
chosen that runs through the apex and the middle of the mitral ring. 
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Figure 3. Four chamber view in systole. 
 
Figure 4. four chamber view in diastole. 
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- Short axis plane: the short axis plane is taken as that which is perpendicular to 
the horizontal long axis and vertical long axis plane.  
 
- True 4 chamber view: in a short axis view, a plane is taken that passes from 
the superior most mitral valve, antero-lateral papillary muscle to the inferior angle of 
the right ventricle anteriorly and through the midpoint of the interventricular septum, 
to get the true 4 chamber view. 
 
- True short axis plane: is taken perpendicular to the true 4 chamber view. No 
single plane is absolutely perpendicular to both the ventricular walls however the 
plane that is positioned parallel to the mitral valve between the anterior and posterior 
atrio-ventricular groove is best. 
 
 - From the true short axis plane, the vertical long axis, horizontal long axis, the 
left ventricular inflow / outflow can be acquired. 
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Figure 5. MRI CINE short axis at systole and diastole at basal, mid-cavity and 
apical levels 
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Cardiac function:  
Cine MRI is used to visualize cardiac motion. It is similar to Echocardiography. 
The main advantage of cine MRI in the myocardial wall motion evaluation and LV 
function when compared to Echocardiography is its ability to sharply delineate 
endocardial borders. This superior quality of cardiac MRI allows us to interpret and 
quantify more accurately and consistently the LV function. Of course the question of 
poor acoustic window does not arise with cardiac MRI. In one particular study that 
assessed quality of the images taken in 208 patients as part of its analysis, showed that 
only 51% of the Echocardiograms were considered to be of good or very good image 
quality, whereas 82% of the MR equivalents were graded highly(15).  
 
Modified Simpson rule- volume of an object can be estimated by taking the sum 
of the cross sectional areas of each section and multiplying by the section thickness. 
(16) 
 
A stack of short axis cine images is taken and the volume is assessed at end 
systole and end diastole. Ejection fraction is calculated as the difference of LV 
volumes at end systole and end diastole divided by the left ventricular volume at end 
diastole. Papillary muscles are included in the blood pool by consensus. The stacks of 
short axis images are acquired in the steady state free precision sequence which results 
in an excellent contrast between the blood pool and the myocardium. This contrast is 
maintained however ischemic or distorted by disease the chamber is. Therefore there 
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is no requirement for geometric assumption at any point in time, making the 
assessment of ejection fraction very accurate and the inter study variation very less. 
 
Cardiac Magnetic Resonance Imaging in Pulmonary Hypertension 
Cardiac Magnetic Resonance Imaging (CMR) is a versatile tool for the 
assessment of the right ventricle. Several studies have shown significant relationships 
between cardiovascular magnetic resonance (CMR) derived measurements with mean 
pulmonary artery pressures (mPAP) and pulmonary vascular resistance (PVR) as 
measured by right heart catheterisation in patients with PH(17).  
Accurate volume measurements of the right ventricle are possible on CMR using 
ECG gated cine imaging where the heart is imaged throughout the cardiac cycle along 
any plane. For routine cardiac imaging, cine images are obtained along the short axis 
of the heart or left ventricle such that it is easy to trace the endocardium of the left 
ventricle for calculation of LV function.  
Endocardium of the right ventricle is more easily traced on true axial images and 
true axial cine images are thought to be better for assessing right ventricular volume 
functions. However, the difference is only in the matter of ease of endocardial tracing 
and there is no significant change in the accuracy compared with volumes traced out 
on short axis cine images.  
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The volumetric data that may be obtained from CMR using appropriate software 
includes the following: 
i) End Diastolic volume of the ventricle 
ii) End systolic volume of the ventricle 
iii) Ventricular stroke volume 
iv) Ventricular ejection fraction 
v) Cardiac output 
 
 
Figure 6. 
Analysis of left ventricular endocardial and epicardial tracings on short axis cine 
images in the End Systolic and End diastolic phases using the SIEMENS post-
processing software called ARGUS. 
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The ventricular mass is obtained by tracing the epicardium in diastole. The right 
ventricular muscle volume is obtained by calculating the volume of the area between 
the epicardium and the endocardium. From this right ventricular mass is obtained by 
multiplying the muscle volume with the specific gravity of the cardiac muscle. 
All of the above values may be indexed or normalised by dividing the value by 
the patient’s body surface area obtained from patient’s height and weight. This renders 
the measurements more comparable between individuals of different statures. 
 
Figure 7. 
Indexed or normalised left ventricular volumes and mass generated by the 
ARGUS post-processing software for SIEMENS along with the normal ranges. 
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Many other indicators of right ventricular function including those used in 
Echocardiogram may also be calculated using CMR. These include: 
 Tricuspid annular plane systolic excursion [TAPSE] calculated on four 
chamber cine images(18). The distance from the tricuspid annulus to the apex 
of the heart is measured in systole and diastole. The systolic value is subtracted 
from the diastolic value and represents the linear movement of the tricuspid 
annulus during contraction. This indicates the longitudinal contraction of the 
right ventricle. 
 
Figure 8. [a] and [b] 
Four chamber views in [a] – systole and [b] – diastole.  
TAPSE is obtained by subtracting the length of the line in [a] from that in [b] 
 Fractional tricuspid annulus-apex distance change [f-TAAD]. This is 
calculated from the above value where the TAPSE is divided by the distance 
between the tricuspid annulus and apex in systole and multiplied by 100 to give 
a percentage value of the same. 
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 Septum-free-wall perpendicular distance [SFD & fractional SFD]. This 
is also calculated on four-chamber CINE images to assess the transverse 
function of the right ventricle. The perpendicular distance from the septum 
midpoint between the apex and base are calculated as the septum-free-wall 
distance [SFD]. Values are obtained in systole and diastole and the difference 
is obtained. Fractional SFD may be calculated by dividing this value by the 
septum to free wall distance in diastole expressed as a percentage. In a study by 
Kind T, et al, right ventricular ejection fraction was thought to be better 
reflected by transverse rather than longitudinal wall motion in the presence of 
pulmonary hypertension (19). 
 
 Figure 9. [a] and [b] 
 Four chamber views in [a] – systole and [b] – diastole.  
 SFD is obtained by subtracting the length of the line in [a] from that in [b] 
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 Left ventricular eccentricity [sEI & dEI]. This is calculated on the short 
axis cine images midway between the base of the heart and the apex. 
Longitudinal distance of the left ventricle parallel to the interventricular septum 
is divided by the perpendicular distance from the midpoint of the 
interventricular septum to the lateral free wall. This measurement is obtained in 
systole and diastole and represents the movement of the interventricular septum 
in systole and diastole. This has also been shown to correlate with pulmonary 
hypertension (20). 
 
 Figure 9. [a] and [b] 
 Short axis views at mid-cavity level in [a] – systole and [b] – diastole.  
 Eccentricity index is obtained by dividing the length of the vertical dotted line 
by the horizontal arrow. 
 
44 
 
 Late Gadolinium Enhancement at septal insertions probably represents 
ischaemic changes at the hinge points of the interventricular septum and are 
seen in pulmonary hypertension. However, this finding is non-specific ad may 
also be seen in other conditions such as hypertrophic cardiomyopathy. 
 A recent article published in the Journal of Cardiovascular Magnetic 
Resonance in the August 2015 edition proposes that the ratio of the diameter of 
the main pulmonary artery to the diameter of the aorta at that level correlates 
with pulmonary hypertension in patients with heart failure (21). 
 
 Figure 9: TRUFISP axial section at the level of the pulmonary artery. 
 Ratio of the length of the dotted line [MPA] over the straight arrow [Aorta] 
gives the Pulmonary artery: Aorta ratio. 
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 Cardiac MRI allows the delineation of the endocardial and epicardial 
borders at each section of the heart that allows the calculation of the muscle 
volume of the ventricles. When this is multiplied by the density of the heart 
muscle, one is thereby able to infer the myocardial mass of each ventricle. The 
interventricular septum is considered to be part of the left ventricle and is 
excluded and from the calculation of the right ventricular mass. The right and 
left ventricular masses thus computed may be divided by the body surface area 
to yield the indexed values. When the right ventricular mass is divided by the 
left ventricular mass, it yields a ratio called the Ventricular Mass Index [VMI]. 
Several studies have shown significant relationships between CMR parameters 
with mean pulmonary artery pressure [mPAP] and pulmonary vascular 
resistance [PVR] as measured on right heart catheterisation including 
ventricular mass index (VMI) (17,22–25). 
 
 Figure 9. Short axis views at mid-cavity level in [a] – systole and [b] – diastole.  
 Endocardium of both ventricles have been traced on the end systolic image 
while epicardium is traced on the end diastolic image (dotted lines) 
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  Inter Venricular Septal Angle. This is measured on the short axis 
images at the mid level in right ventricular systole. A line is drawn from the 
anterior and posterior hinge points of the right ventricular free wall to the 
midpoint of the interventricular septum. The angle formed between these two 
lines towards the left ventricle is measured. This angle becomes more obtuse 
with increase in right ventricular pressures. Several studies have shown 
significant relationships between mean pulmonary artery pressure [mPAP] and 
pulmonary vascular resistance [PVR] as measured on right heart catheterisation 
with the inter-ventricular septal configuration (26–28).  
 
 Figure 10. Short axis view in systole demonstrating the measurement of 
angle of the interventricular septum 
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Phase contrast imaging 
Phase contrast imaging also known as velocity encoded imaging has been used 
in Pulmonary Hypertension for pulmonary arterial blood flow quantification and 
plasticity. Through-plane velocity measurements are obtained from the main 
pulmonary artery and analysed using the post-processing software. This analysis will 
yield the following measurements for the pulmonary artery: 
a) Peak velocity 
b) Average velocity 
c) Forward volume 
d) Reverse volume 
e) Minimum area of the pulmonary artery 
f) maximum area of the pulmonary artery 
From the above mentioned measurements, the following additional calculations 
can be made: 
1) Forward volume – reverse volume = net forward volume. This corresponds to 
the right ventricular stroke volume 
2) Reverse volume/ forward volume * 100 = percentage retrograde flow 
3) Pulmonary artery distensibility = maximum area – minimum area of the 
pulmonary artery. 
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4) Maximum area – minimum area/ minimum area of the pulmonary artery = 
relative area change of the pulmonary artery  
These values have been shown to have a high degree of correlation with mean 
pulmonary artery pressure (mPAP) and PVR measurements obtained at right heart 
catheterisation (24,29–32).  
A large retrospective study has compared the multiple CMR parameters with 
Echocardiography and Right Heart Catheterisation and has shown sensitivity and 
specificity of up to 88% for some of these parameters (33). 
Another recent large retrospective study has derived a formula to calculate mean 
pulmonary artery pressure (mPAP) from various right heart parameters measured on 
CMR: 
CMR-predicted mPAP = - 4.6 + (interventricular septal angle x 0.23) + 
(ventricular mass index x 16.3) (34). 
This formula suggests that the main factors affecting the pulmonary arterial 
pressures are those related to the right ventricular muscle mass in relation to that of 
the left ventricle and the interventricular septal bounce or bowing during systole. 
These measurements can therefore be made on the regular short axis CINE images 
acquired for the calculation of left ventricular ejection fraction on routine cardiac 
MRI. Consequently, these values may be computed retrospectively even if the patient 
was not known or suspected to have pulmonary hypertension at the time of imaging. 
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Patients and methods 
Study Design: Study of Correlation 
Study Type: Analytical and descriptional 
Setting of study:  
 Christian Medical College (CMC) Vellore is a tertiary teaching hospital in 
Tamil Nadu, 80miles west of Madras. It was established in 1900 by Dr. Ida Sophia 
Scudder, a Christian Missionary from the United States of America to educate Indian 
women to treat Indians. It is now a Quaternary level referral centre with 2700 beds 
and around 8000 outpatients a day.  
The Department of Radiology in CMC, Vellore was established in 1936 and 
became “filmless” in the year 2000 with the introduction of PACS (Picture Archival 
and Communication System). It functions as a single unit with approximately 75 
radiologists and 20 postgraduates, over a hundred radiographers besides other staff. 
Our department has two 1.5 tesla and one 3tesla MRI scanners. Approximately 
3000 MRI examinations are performed every month including emergencies. Cardiac 
MRI is performed on the 1.5tesla SIEMENS machine and post-processed using the 
ARGUS software.  
In the study period between July 2014 and August 2015, a total of 366 cardiac 
MRI examinations were performed, mostly for ischaemic heart disease.  
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Inclusion criteria: 
1) Consecutive adult patients undergoing Right Heart 
Catheterisation for any indication during the study period. 
2) Consecutive adult patients suspected with pulmonary 
hypertension on Cardiac MRI performed for any indication during the study 
period. 
3) Those of the above who have a comparison Echocardiogram 
 
Exclusion criteria: 
1) Patients who have contra-indications for MRI such as MR 
incompatible implants, aneurysm clips or pacemakers 
2) Paediatric patients who may require anaesthesia for Cardiac MRI 
3) Patients who refuse cardiac MR  
4) Those who do not have a comparison study, either an 
echocardiogram or right heart catheterisation 
5) Those who have significant additional abnormality on cardiac 
MRI such as congenital heart disease or myocardial infarction that would 
interfere with accurate measurements on MRI 
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Methodology  
 
Sampling & Consent 
 Pulmonary hypertension is relatively rare and right heart catheterisation for the 
same is even rarer. Therefore all patients who underwent right heart catheterisation for 
any indication, for whom pulmonary pressures were measured and who fulfilled the 
inclusion criteria were invited to participate in the study. No specific sampling 
strategy was employed to enroll such patients. However, many patients could not be 
included due to lack of machine time and competent personnel for performing the 
study. Informed written consent was obtained from the patient or patient’s guardian 
prior to MRI. 
Other patients who were suspected to have pulmonary hypertension after they 
had cardiac MRI on routine reporting were included retrospectively if they fulfilled 
the inclusion criteria and had none of the exclusion criteria. Consent was reckoned 
obtained by implication. 
The consent form along with the Patient Information sheet is attached in 
Annexture section. 
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Cardiac MRI 
(i) MRI scanner 
Cardiac MRI was performed at our institution in a 1.5T scanner 
(Avanto, SIEMENS Systems, Germany). Patients were positioned supine in 
the head first position. They were connected to ECG leads and pulse 
oximetry throughout the period of image acquisition.  
 
(ii) Coils 
 1.5T – 16 channel body array anterior MRI coils were used 
 
(iii) MRI Sequence protocol 
 The MRI protocol included the following sequences 
2D TRUFISP AXIAL OF THORAX  
Field of view (FOV) was set at 400mm; slice thickness 6mm with slice gap of 
1.2mm; TR (repetition time) of 161.83ms and TE (Echo time) of 1.17ms; Acquisition 
matrix 136 x 256. Imaging was performed with ECG triggering and breath holds. 
Acquisition window was 850. Trigger pulse was 1 with a trigger delay of 688. Scan 
time was 50 seconds with varying concatenations, depending on the patient’s 
condition (concatenation – number of breath holds). 
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2 CHAMBER VIEW 
A single slice is prescribed from the TRUFISP axial view. A line was drawn 
prescribed parallel to the ventricular septum bisecting the left ventricle through the 
mitral valve and apex to get a view consisting of 2 chambers, the left atrium and 
ventricle. 
 
 
 (a) (b) 
Figure 11:  
Obtaining the 2 chamber view.  
(a) 2D TRUFISP axial through thorax  
(b) 2 chamber view  
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4 CHAMBER VIEW 
A slice was then prescribed from the 2 chamber view. A line was drawn 
bisecting the left ventricle through the mitral valve and apex to generate a view 
consisting of all the four chambers, the left atrium, left ventricle, right atrium and the 
right ventricle.  
 
 (a) (b)  
Figure 12:  
Obtaining the 4 chamber view.  
(a) 2 chamber view  
(b) 4 chamber view 
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SHORT AXIS SECTION 
Stack of slices placed perpendicular to the long axis of the left ventricle were 
obtained from the mitral valve to the apex.  
  
 (a) (b)  
    (c) 
Figure 13:  
Obtaining the short axis view. (a) 4 chamber view (b) 2 chamber view (c) short 
axis view 
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Following this Phase-contrast imaging is performed through the main pulmonary 
artery to calculate velocity measurements. Velocity encoded [VENC] image 
acquisition with velocity adjustments ranging from 300 to 450 are obtained as through 
plane images of the main pulmonary artery. MAG images acquired simultaneously are 
sent along with the phase contrast images to the workstation as a data set. 
 
Figure 14. 
Synchronised MAG & phase contrast images through the main pulmonary 
artery. 
Summary of CMR sequences 
SSFP True axial and short axis cine images 
Phase contrast Through plane velocity encoded images through the main 
pulmonary artery 
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(iv)  Image Interpretation 
1. Ventricular volumes and function:  
The ventricular volume and mass measurements will be calculated by the 
Siemens 1.5 T MRI machine specific software which is a dedicated software 
provided by the same company. The software used is Argus software (Siemens, 
Erlangen Germany AG) .This software is already validated, being used widely 
internationally and is approved by the SCMR (Society for Cardiac Magnetic 
Resonance Imaging) 
The short axis cine images are loaded onto the ARGUS volumetric analysis 
application in the workstation that arrays the entire series of images from the cine 
stack in a grid, where mages proceed from base to apex along the rows and 
through the heart cycle along the columns. The End Diastole is usually selected by 
the software based on the ECG gating and is displayed along the first column. The 
software arbitrarily calculates the End Systole series which can be modified by the 
image interpreter through visual analysis. Once the End Diastole and End Systole 
have been ascertained, the outline of the endocardium and the epicardium are 
traced using the drawing tools provided by the software.  
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 Figure 15.  
 Short axis views at mid-cavity level in [a] – systole & [b] – diastole.  
 Endocardium of both ventricles have been traced on the end systolic image 
while epicardium is traced on the end diastolic image (dotted lines) 
In the End diastole series, the epicardium and endocardium are traced for 
both the right and the left ventricles. The first section is selected where the 
ventricular wall is seen surrounding at least 50% of the cavity. If part of the aorta 
or the pulmonary artery is included in the image, these portions are excluded from 
the tracing. In the left ventricle, the papillary muscles and trabeculae are included 
within the endocardium according to convention. The inter-ventricular septum is 
included within the epicardial tracing for the left ventricle and excluded from the 
right ventricle according to convention. As much as is reasonably feasible, the 
trabeculations in the right ventricle are included as part of the right ventricular 
mass and not included within the endocardium. Tracings are drawn upto the apex.  
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 Figure 16.  
 Short axis views at mid-cavity level in [a] – diastole & [b] – systole in a patient 
with pulmonary hypertension and mild pericardial effusion 
 Endocardium and epicardium(dotted lines) of the right ventricle is traced on the 
end diastolic image  
 Note that the interventricular septum forms part of the left ventricular wall and 
is hence not included in the right ventricle mass. 
 
In the End systole series, the endocardium alone is traced for both the right 
and left ventricles as stated above, from the base to the apex, excluding portion of 
the aorta and the pulmonary artery. 
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2. The ARGUS software then analyses the tracings and analysis will yield 
the following measurements for right and left ventricles separately: 
a) Ventricular end diastolic volume [EDV] obtained by multiplying 
the sum of the areas within the endocardial outline by slice thickness at End 
Diastole 
b) Ventricular end systolic volume [ESV] obtained by multiplying 
the sum of the areas within the endocardial outline by slice thickness at End 
systole 
c) Ventricular mass at end diastole, which is obtained by 
multiplying ventricular myocardial volume at end diastole by 1.05 [specific 
gravity of cardiac myocardium]. The ventricular myocardial volume is 
obtained by multiplying with slice thickness with the sum of areas between the 
endocardial and epicardial tracings. 
3. From the above measurements, the following additional calculations are 
generated by the software for both ventricles:  
b) Stroke volume [SV] = EDV – ESV 
c) Ejection fraction = EDV – ESV/ EDV 
d) Indexed ventricular volumes and masses obtained by dividing the 
desired value by the patient’s body surface area. 
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4. The following additional measurements and calculations that are not 
provided by the software are also made: 
a. Interventricular septal angle. This is measured in the systolic 
phase midway between the base of the heart and the apex. A line is drawn 
connecting the anterior and posterior hinge points with the midpoint of the 
setum. The angle sustained between these two lines is the interventricular 
septal angle. 
b. Systolic eccentricity index [sEI]. This is measured in the systolic 
phase midway between the base of the heart and the apex. A line is drawn 
from the midpoint of the inter-ventricular septum perpendicularly towards 
the lateral wall and the distance between the endocardial surfaces is 
measured as D1. The longest transverse axis perpendicular to this line is 
also measured along a line parallel to the interventricular septum as D2. 
Eccentricity index is obtained by dividing D1 by D2. 
c. Diastolic eccentricity index [dEI]. This is measured similar to the 
above in the diastolic phase. 
d. Ventricular mass index [VMI]. This ratio is obtained by dividing 
the right ventricular mass in diastole by the left ventricular mass in 
diastole. 
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5. Phase contrast images through the pulmonary artery will be analysed 
using the Siemens 1.5 T MRI machine specific software which is dedicated 
software provided by the same company. The software used is Argus software 
(Siemens, Erlangen Germany AG) .This software is already validated, being used 
widely internationally and is approved by the SCMR (Society for Cardiac 
Magnetic Resonance Imaging). Pulmonary artery outline in cross-section is traced 
throughout the cardiac cycle on MAG images and these are then projected onto the 
phase contrast images. This analysis will yield the following measurements: 
a) Peak velocity in the pulmonary artery. 
b) Average velocity in the pulmonary artery. 
c) Forward volume in the pulmonary artery. 
d) Reverse volume in the pulmonary artery. 
e) Minimum area of the pulmonary artery 
f) maximum area of the pulmonary artery 
6. From the above mentioned measurements, the following additional 
calculations are made: 
a) Forward volume – reverse volume = net forward volume. This 
corresponds to the right ventricular stroke volume 
b) Reverse volume/ forward volume * 100 = percentage retrograde flow 
63 
 
c) Maximum area – minimum area/ minimum area of the pulmonary artery 
= relative area change of the pulmonary artery 
The Argus software also generates the following analysis from flow studies: 
1. Flow vs. time curve 
2. Velocity vs. time curve 
3. Area vs. time curve 
4. Peak flow vs. time curve 
5. Peak velocity vs. time curve 
CMR-predicted mean pulmonary artery pressure (mPAP) is then calculated from 
various right heart parameters using the formula which has been deducted in a recent 
large multicentric retrospective study as mentioned in the literature review. 
CMR-predicted mPAP = -4.6 + (IVS angle x 0.23) + (VMI x 16.3)  
Where mPAP stands for mean pulmonary arterial pressue, IVS for 
interventricular septum and VMI for ventricular mass index. 
Each of the above parameters is then compared against the mean pulmonary 
artery pressure (mPAP) measured on Echocardiogram and right heart catheterisation 
when available. 
 
 
64 
 
Detailed diagrammatic Algorithm of the study  
 
 
                  Right Heart Catheterisation 
CMR for other indications 
Informed about the project and invited to volunteer 
Pulmonary hypertension 
              written informed consent 
Echocardiography  
      CMR for Pulmonary hypertension 
 
Analysis and Interpretation by Primary Investigator  
 
Verification & approval by Consultant Radiologist (Guide) 
 
Results informed to treating physician   Statistical analysis 
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Analysis and results 
Chart demonstrating the enrollment of subjects in the study 
 
  
366 
•total number of CMR 
performed from July 2014 to 
August 2015 
29 
•suspected or diagnosed to have 
pulmonary hypertension 
22 
•7 excluded due to exclusion 
criteria 
18 
•4 did not have both 
echocardiogram and right 
heart catheterisation for 
comparison 
20 
•2 volunteer subjects included 
after right heart 
catheterisation 
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Demographic data: 
Total number of subjects who were analysed: 20 adults 
Men - 65% 
Women – 35% 
Gender distribution: 
 
Figure 17 
 
 
 
 
13 
7 
male female 
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Age distribution: 
Mean 45.30 
Median 48.00 
Std. Deviation 12.876 
Minimum 23 
Maximum 63 
Percentiles 25 32.50 
50 48.00 
75 57.25 
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Echocardiogram parameters: 
At least half of those analysed had pulmonary hypertension according to 
pressures measured on Echocardiography 
Statistics 
 Tricuspid 
regurgitant jet 
velocity 
Pressure 
gradient across 
the tricuspid 
valve 
Pulmonary 
artery systolic 
pressure 
Mean 
pulmonary 
arterial pressure 
Mean 311.990 42.990 49.140 31.955 
Median 290.000 33.750 42.050 27.700 
Std. Deviation 99.5152 30.2190 30.1800 18.3668 
Minimum 183.0 13.4 18.4 13.2 
Maximum 559.0 125.0 130.0 81.0 
Percentiles 
25 238.750 22.825 29.500 19.975 
50 290.000 33.750 42.050 27.700 
75 356.325 54.275 61.975 39.850 
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Correlation between mean pulmonary artery pressure (mPAP) measured 
on Echocardiogram & MPA diameter on CMR 
 
Echocardiogram derived mean Pulmonary artery pressure is expressed in mmHg. 
Main pulmonary artery diameter is expressed in mm. 
Pearson’s co-efficient of correlation = 0.635 
Significance (p value) = 0.003 
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Correlation between mean pulmonary artery pressure (mPAP) measured 
on Echocardiogram & MPA diameter on CMR 
 
 
This chart shows the near total overlap of the curves suggesting a fairly high 
degree of correlation between the values even in the absence of pulmonary 
hypertension; i.e., normal individuals. 
 
 
 
echompap mpa 
71 
 
Correlation between mean pulmonary artery pressure (mPAP) measured 
on Echocardiogram and ratio of the diameter of main pulmonary artery to that 
of ascending Aorta at the same level as measured on CMR 
 
Echocardiogram derived mean Pulmonary artery pressure is expressed in mmHg. 
Ratio of main pulmonary artery diameter to diameter o the aorta is on y axis.  
Pearson’s co-efficient of correlation = 0.716 
Significance (p value) = less than 0.001 
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Correlation between mean pulmonary artery pressure (mPAP) measured 
on Echocardiogram & indexed right ventricular mass at end diastolic measured 
on CMR 
 
Echocardiogram derived mean Pulmonary artery pressure is expressed in mmHg. 
Right ventricular end diastolic mass index is expressed in g/m2 
Pearson’s co-efficient of correlation = 0.446 
Significance (p value) = 0.049 
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Correlation between mean pulmonary artery pressure (mPAP) measured 
on Echocardiogram and ventricular mass index [VMI] computed from 
measurements on CMR 
 
Echocardiogram derived mean Pulmonary artery pressure is expressed in mmHg. 
Ventricular mass index is expressed as a ratio. 
Pearson’s co-efficient of correlation = 0.783 
Significance (p value) = less than 0.001 
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Correlation between mean pulmonary artery pressure (mPAP) measured 
on Echocardiogram and systolic eccentricity index [sEI] computed from 
measurements on CMR 
 
Echocardiogram derived mean Pulmonary artery pressure is expressed in mmHg. 
Systolic eccentricty index is expressed as a ratio. 
Pearson’s co-efficient of correlation = 0.605 
Significance (p value) = 0.005 
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Correlation between mean pulmonary artery pressure (mPAP) measured 
on Echocardiogram and inter-ventricular septal angle measured on CMR 
 
Echocardiogram derived mean Pulmonary artery pressure is expressed in mmHg. 
Inter-ventricular septal angle is expressed on the y axis. 
Pearson’s co-efficient of correlation = 0.577 
Significance (p value) = 0.008 
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Correlation between mean pulmonary artery pressure (mPAP) measured 
on Echocardiogram and that derived from parameters measured on CMR 
 
Echocardiogram derived mean Pulmonary artery pressure is expressed in mmHg. 
CMR derived mean Pulmonary artery pressure is expressed in mmHg. 
Pearson’s co-efficient of correlation = 0.713 
Significance (p value) = less than 0.001 
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Correlation of CMR parameters with mean pulmonary artery pressure 
(mPAP) measured on Echocardiography and their significance 
CMR Parameter Pearson 
correlation 
Significance  
Right ventricular ejection fraction -0.189 0.426 
Right ventricular end diastolic volume 0.169 0.477 
Right ventricular end systolic volume 0.188 0.427 
Right ventricular stroke volume 0.102 0.669 
Right ventricular mass in end diastole 0.431 0.058 
Right ventricular end diastolic volume index 0.19 0.421 
Right ventricular end systolic volume index 0.199 0.4 
Right ventricular stroke volume index 0.14 0.555 
Left ventricular ejection fraction 0.108 0.649 
Left ventricular end diastolic volume -0.15 0.528 
Left ventricular end systolic volume -0.056 0.816 
Left ventricular stroke volume -0.172 0.467 
Left ventricular mass in end diastole -0.235 0.319 
Left ventricular end diastolic volume index -0.14 0.556 
Left ventricular end systolic volume index -0.055 0.818 
Left ventricular stroke volume index -0.15 0.529 
Left ventricular mass index -0.217 0.359 
Diastolic eccentricity index .492* 0.028 
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Multivariate analysis of the CMR parameters whose correlation with 
Echocardiogram derived mean pulmonary artery pressure (mPAP) was 
statistically significant 
 
Model Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
B Std. 
Error 
Beta 
1 
(Constant) 23.636 40.406  .585 .568 
Pulmonary Artery to Aorta 
Diameter Ratio 
20.951 15.276 .298 1.372 .192 
Ventricular mass index 42.555 56.179 .614 .757 .461 
Systolic eccentricity index -10.097 19.109 -.205 -.528 .605 
Interventricular septal angle -.451 .808 -.457 -.558 .586 
CMR derived mPAP 1.157 2.720 .542 .425 .677 
 
Though the above parameters were individually significant, multivariate analysis 
was not significant. 
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Right heart catheterisation measurements 
Of the 20 subjects studied, 6 patients underwent right heart catheterisation. 
Statistics 
 Age of the 
patient 
Peak systolic 
pressure 
Diastolic 
pressure 
mPAP 
Mean 
45.30 61.000 25.833 38.0000 
Median 
48.00 40.500 20.000 29.0000 
Std. Deviation 
12.876 45.2593 16.4124 25.13961 
Minimum 
23 31.0 12.0 18.00 
Maximum 
63 149.0 57.0 86.00 
Percentiles 
25 32.50 34.000 15.000 21.0000 
50 48.00 40.500 20.000 29.0000 
75 57.25 89.750 36.750 54.5000 
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Correlation between mean pulmonary artery pressure (mPAP) measured 
on right heart catherisation and ventricular mass index computed from 
measurements on CMR 
 
Right heart catherisation derived mean Pulmonary artery pressure is expressed in 
mmHg. 
Ventricular mass index is represented as a ratio on the y axis. 
Pearson’s co-efficient of correlation = 0.934 
Significance (p value) = 0.006 
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Correlation between mean pulmonary artery pressure (mPAP) measured 
on right heart catherisation and systolic eccentricity index computed from 
measurements on CMR 
 
mean Pulmonary artery pressure measured on Right heart catherisation is 
expressed in mmHg. 
Systolic eccentricity index is represented as a ratio on the y axis. 
Pearson’s co-efficient of correlation = 0.93 
Significance (p value) = 0.007 
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Correlation between mean pulmonary artery pressure (mPAP) measured 
on right heart catheterisation and mPAP computed from measurements on CMR 
 
Mean Pulmonary artery pressure [mPAP] is expressed in mmHg. 
Pearson’s co-efficient of correlation = 0.916 
Significance (p value) = 0.01 
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Other significant correlations between CMR parameters and mean 
pulmonary artery pressure (mPAP) measured on right heart catheterisation 
 
CMR parameter Pearson correlation Significance (2-tailed) 
Main pulmonary artery diameter  .908* 0.012 
Pulmonary artery to aorta ratio .895* 0.016 
Diastolic eccentricity index .910* 0.012 
Interventricular septal angle .912* 0.011 
 
Although the number of subjects who underwent right heart catheterisation is 
small, these values show significant association suggesting a real linear association 
between the mentioned CMR parameters and severity of pulmonary hypertension. 
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Multivariate analysis of the statistically significant correlation CMR 
parameters with mean pulmonary artery pressure (mPAP) 
Model Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
B Std. Error Beta 
1 
(Constant) 35.374 66.558  .531 .603 
Pulmonary Artery to 
Aorta Ratio 
34.292 25.164 .297 1.363 .194 
Ventricular mass index 70.058 92.540 .616 .757 .462 
Systolic eccentricity index -16.676 31.477 -.206 -.530 .605 
Intervtricular septal angle -.737 1.331 -.455 -.553 .589 
CMR derived mPAP 1.894 4.481 .539 .423 .679 
 
Though the above parameters were individually significant, multivariate analysis 
was not significant. 
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Correlation between mean pulmonary artery pressure (mPAP) measured on 
right heart catherisation and that measured on Echocardiogram 
 
Mean Pulmonary artery pressure [mPAP] is expressed in mmHg. 
Sensitivity = 100% 
Specificity = 50% 
Positive predictive value = 80% 
Negative predictive value = 100% 
 
y = 0.8674x + 13.322 
R² = 0.6669 
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 Discussion 
A total of 366 cardiac magnetic resonance imaging [CMR] was performed 
during the study period from July 2014 to August 2015. A total of 29subjects either 
underwent CMR with a clinical suspicion of pulmonary hypertension or were 
suspected or diagnosed on CMR with the same. Of these, 7 subjects had one or more 
exclusion criteria such as congenital heart disease or significant myocardial infarction. 
Of the remaining 22subjects, 4 did not have Echocardiographic measurements for 
calculation of mean pulmonary artery pressure (mPAP). 18 patients had both CMR 
and Echocardiogram with values for calculating mean pulmonary artery pressure 
(mPAP). 
Five subjects who were planned for right heart catheterisation were invited to 
participate in the study and undergo CMR. Two of these subjects refused consent. Of 
the three patients who consented to be subjects, right heart catheterisation was 
deferred for one patient. Hence 2 voluntary subjects entered the final analysis.  
A total of 20subjects had both MRI and Echocardiogram and underwent 
statistical analysis for correlation. All were adults and there were more men than 
women. A total of 12subjects (60%) had Echocardiogram derived mean pulmonary 
artery pressure (mPAP) more than 25mmHg calculated by the standard formula 
specified in the methodology and the remaining had values less than 25mmHg. 
Six of the subjects underwent right heart catheterisation and four of them had 
pulmonary hypertension which is 67% 
87 
 
Accuracy of CMR derived mean pulmonary artery pressure (mPAP) 
The formula for derivation of mean pulmonary artery pressure on CMR is taken 
from a study by Swift et. al published in October 2013 called Non-invasive estimation 
of pulmonary artery pressure, flow and resistance using CMR (34). According to this 
formula all the studied subjects had a CMR derived mean pulmonary artery pressure 
(mPAP) of more than 25mmHg. This suggests a high sensitivity, however a low 
specificity. That is to say that this value overestimates the pulmonary pressure and 
balances with the Echo derived values at a cutoff value of around 34mmHg. However, 
this value compared with the mean pulmonary artery pressure derived showed a high 
degree of linear correlation with p value of 0.001.  
The formula for derivation of mean pulmonary artery pressure on CMR uses two 
CMR parameters for its computation, viz., ventricular mass index [VMI] and 
interventricular septal angle. VMI shows a high degree of correlation with p value of 
less than 0.001, which is similar to other studies as detailed in the literature review. A 
recent systematic review suggests that the cut off value is 0.45 (35). 
Interventricular septal angle also shows significant correlation, though less than 
VMI, with a p value of 0.008. Interventricular septal angle in systole is an indicator of 
septal bowing or bounce seen when there is pulmonary hypertension as the septum 
bulges more and more into the left ventricle with rising pressures causing the left 
ventricle to lose its circular nature on short axis and be deformed in systole becoming 
elongated parallel to the septum. This property is more accurately measured by the 
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eccentricity index in systole and shows a higher degree of correlation with mean 
pulmonary artery pressure (mPAP) with a p value of 0.005. 
CMR derived mean pulmonary artery pressure (mPAP) compared with catheter 
derived mean pulmonary artery pressure (mPAP) also showed significant correlation 
with p value of 0.01 though the sample size for comparison was small. According to 
this formula all the studied subjects had a CMR derived mean pulmonary artery 
pressure (mPAP) of more than 25mmHg. This suggests a high sensitivity, however a 
low specificity. That is to say that this value overestimates the pulmonary pressure. 
However, owing to the small number of subjects studied, it is difficult to comment on 
the accuracy. 
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Correlation between CMR parameters and Echocardiogram derived mean 
pulmonary artery pressure (mPAP) 
Highest correlation with a p value of less than 0.001 was seen for the following 
CMR parameters: 
(1) Ratio of the diameter of the main pulmonary artery to that of the 
ascending aorta at the same level 
(2) Ventricular mass Index 
High degree of correlation, with a p value of less than or equal to 0.01 was seen 
for the following CMR parameters: 
(1) Main pulmonary artery diameter on MRI 
(2) Systolic eccentricity index 
(3) Interventricular septal angle 
Significant correlation with a p value of less than or equal to 0.05 was also seen 
for the following CMR parameters: 
(1) Diastolic eccentricity index 
(2) Normalised or indexed right ventricular mass in end diastole. 
Main pulmonary artery diameter, though often measured by radiologists, is not 
considered important by the cardiologists and therefore significant correlation 
demonstrated on this study is favourable. However, this same measure, when 
expressed as a ratio over the diameter of the ascending aorta at the same level is of 
much more significance. 
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The other two main categories of parameters of significance are those related to 
the right ventricular mass and septal bowing. 
Right ventricular mass in itself showed only moderately significant correlation 
with a p value of 0.058 which increased to p value of 0.049 when indexed. However, 
when this is expressed as a ratio over the left ventricular mass in diastole as 
ventricular mass index, it shows a high degree of correlation. Owing to this, the 
significance of right ventricular mass in the presence of significant left ventricular 
infarction is doubtful and may be misleading. 
The other category of parameters of significance related to septal bowing or 
bounce includes the angle of the interventricular septum in systole and the eccentricity 
indices. In our study, systolic eccentricity index appears to be a marginally better 
indicator of septal bowing than the angle of the interventricular septum in systole, 
with loss in p value from 0.008 to 0.005. interestingly, the diastolic eccentricity index 
also shows a moderate significance of 0.028 suggesting right ventricular diastolic 
dysfunction. This function is also susceptible for error in the presence of significant 
regional or global wall motion abnormality in the presence of ischaemic heart disease. 
Right ventricular volumes and function did not show significant correlation with 
mean pulmonary artery pressure (mPAP) measured on Echocardiogram in our study. 
The left ventricular volumes function and masses also did not show significant 
correlation with mean pulmonary artery pressure (mPAP) measured on 
Echocardiogram in our study. 
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Correlation between CMR parameters and mean pulmonary artery 
pressure (mPAP) measured on right heart catheterisation 
The sub-set of patients who underwent right heart catheterisation was small, 
being only 6. However, similar parameters such as ratio of main pulmonary artery 
diameter to ascending aorta, ventricular mass index and those related to septal bowing 
were found to be statistically significant. 
High degree of correlation between mean pulmonary artery pressure (mPAP) 
measured on Echocardiogram and catheterisation was also observed in our study. 
Accuracy of diagnosis of pulmonary hypertension defined as mean pulmonary artery 
pressure (mPAP) more than 25 showed 100% sensitivity and negative predictive 
value. However specificity was only 50%. 
 
Phase contrast imaging 
In our study phase contrast analysis and values showed no statistically 
significant correlation with mean pulmonary artery pressure (mPAP). However the 
subset of patients who underwent phase contrast imaging is very small and therefore 
any statistical inference is deemed insignificant.  
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Figure 18 
Graph showing velocity in cm/sec plotted against time in milliseconds in a 
patient with pulmonary hypertension due to mitral valve stenosis who underwent 
phase contrast imaging through the main pulmonary artery. 
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Qualitative assessment of CMR in those diagnosed with pulmonary 
hypertension based on Echocardiogram derived mean pulmonary artery 
pressure (mPAP) of more than 25mmHg. 
1) On the axial images, the size of the main pulmonary artery appeared equal to or 
greater than that of the ascending aorta at the same level 
2) Right ventricular hypertrophy was more apparent rendering the tracing of the 
endocardium and the epicardium of the right ventricle more easy and accurate 
3) The papillary muscles and trabeculations of the right ventricle including the 
moderator band appeared larger and more prominent than in those with normal 
pressures. 
4) Septal bounce was well appreciated on short axis CINE images in those with 
pulmonary hypertension, especially when played as a video. 
5) Loss of circular contour of the left ventricle in systole was also well appreciated in 
short axis CINE images in those with pulmonary hypertension 
6) The right ventricle appearing larger in end diastole was more often seen in those 
with pulmonary hypertension than in normal subjects, especially in relation to the 
left ventricle 
7) In phase contrast imaging, patients with pulmonary hypertension appeared to have 
larger cross sectional area of the main pulmonary artery both in systole and 
diastole.  
8) Those with higher pulmonary pressures appeared to have proportionately higher 
peak systolic velocity. 
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Limitations 
1) The small sample size of the study is a major draw-back for this study. This is, 
however inevitable considering the time constrains and he rarity of the condition. 
Especially, the subset who underwent the Gold standard reference study is too 
small to infer any statistical analysis of significance. 
2) Pulmonary pressures are known to very on a daily basis. But  Echocardiography 
was performed several days prior to CMR or right heart catheterisation. This limits 
the direct comparison of the diagnostic accuracy of CMR versus Echocardiography 
for the detection of PH.  
3) Echocardiography is a well-established screening tool in the evaluation of patients 
with suspected PH, and treatment is often started based on this. Implementation of 
CMR as a replacement for Echocardiography would be associated with several 
challenges, including cost, availability and expertise.  
4) The right ventricular free wall is barely visible in the end diastolic images in 
normal subjects and therefore diastolic mass is liable to be over-estimated. This 
will reduce the statistical significance of right ventricular mass, thereby the 
ventricular mass index and consequently the CMR derived mean pulmonary artery 
pressure (mPAP).  
5) Since all the subjects analysed had CMR derived mean pulmonary artery pressure 
(mPAP) higher than 25mmHg, this formula though showing a high degree of 
correlation with mean pulmonary artery pressure (mPAP) likely overestimates the 
pressures. 
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Conclusions 
CMR is a versatile tool in the assessment of parameters that indicate right heart 
status and function which correlate well with measurement of mean pulmonary 
arterial pressures on Echocardiography and therefore may be used to diagnose and 
prognosticate pulmonary hypertension.  
Ratio of the diameter of the main pulmonary artery to that of the ascending aorta 
at the same level and Ventricular mass Index showed the highest degree of correlation 
with mean pulmonary arterial pressures on Echocardiography and right heart 
catheterisation when available. Other significant parameters include those related to 
the motion of the interventricular septum in systole. 
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Appendices  
Data collection form 
 
 
Identification number                                     
 
Name of the patient                                          
 
Hospital number                                  
 
Gender of the patient                                            
 
Age of the patient                                            
 
 
Right heart catheterisation  
 
Peak systolic pressure         
 
Diastolic pressure                                          
 
Mean pulmonary arterial pressure                            
 
 
Echocardiogram 
 
Tricuspid regurgitant jet velocity                            
 
Pressure gradient across the tricuspid valve                  
 
Pulmonary artery systolic pressure                            
 
Mean pulmonary arterial pressure                           
 
 
CMR 
 
Main pulmonary artery diameter on MRI                        
 
Pulmonary artery to aorta ratio                               
 
 
Right ventricular ejection fraction                          
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Right ventricular end diastolic volume                   
 
Right ventricular end systolic volume                        
 
Right ventricular stroke volume                              
 
Right ventricular mass in end diastole                       
 
Right ventricular end diastolic volume index                 
 
Right ventricular end systolic volume index                  
 
Right ventricular stroke volume index                        
 
Right ventricular mass index                                 
 
 
Left venricular ejection fraction                           
 
Left ventricular end diastolic volume                        
 
Left ventricular end systolic volume                         
 
Left ventricular stroke volume                               
 
Left ventricular mass in end diastole                        
 
Left ventricular end diastolic volume index                  
 
Left ventricular end systolic volume index                   
 
Left ventricular stroke volume index                         
 
Left ventricular mass index                                  
 
 
Ventricular mass index                                       
 
 
Intervtricular septal angle                                    
 
Systolic eccentricity index                                  
 
Diastolic eccentricity index                                  
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Phase contrast imaging  
 
Phase contrast peak velocity                                 
 
Phase contrast average velocity                                
 
Phase contrast forward volume                                  
 
Phase contrast reverse volume                                   
 
Percentage retrograde flow                                   
 
Phase contrast net forward volume                              
 
Phase contrast net forward volume indexed                    
 
Pulmonary artery systolic area                                 
 
Pulmonay artery diastolic area                                 
 
Pulmonary area distensibility                                  
 
Phase contrast pulmonary artery relative area change         
 
 
 
CMR derived mpap                                              
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Tamil Patient information sheet and consent form 
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    _____________________________  
1.                                        
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                   : _________________________ 
  
  
  
              : ___________________________ 
  
   : _____ / _____ / _______ 
  
           &    : ______________________________ 
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English patient information sheet and consent form 
 
Patient information sheet 
Study title: Role of Cardiac MRI in Pulmonary Hypertension 
The following information is provided to inform you about this study and your 
participation in it. Please read the information carefully and you are free to ask 
questions regarding the study and the information given. Participation in this study is 
purely voluntary and you are free to withdraw from the study anytime. 
 
Purpose of the study 
Cardiac MRI is a non-invasive test which is useful for taking various measurements of 
the heart and making various calculations in pulmonary hypertension. The results of 
this scan will help your doctor to know more about your disease condition and treat 
you better. The results of this study will also help to treat other patients with similar 
illnesses better. 
 
What is cardiac MRI? 
Cardiac MRI is a non-invasive test which is useful for taking various measurements of 
the heart and making various calculations in pulmonary hypertension. The MRI 
machine is a tube with a central opening that is about three feet wide. The patient lies 
on the table and the table slides into the central opening. Pictures of the heart are 
created using a magnetic field, radio waves and computers. X-Rays are not used in 
this scan at all. These images will allow the doctor to know more about the structure 
and function of your heart and treat you better. 
108 
 
What are the risks involved in undergoing this test? 
There are no specific risks particular for this kind of scanning. 
 
Confidentiality 
Your participation in this study will remain confidential and shall be known only to 
the investigators. The results of the study will be published in medical journals, but 
your personal identity such as name and address will not be disclosed to anyone. 
 
Withdrawal from the study 
Participation in this study is purely voluntary and you can withdraw from the study 
anytime without explaining any reasons. It will not compromise your treatment in any 
way.  
 
Additional costs 
Cardiac MRI is done free of charge for you. You will not need to pay any extra 
charges. 
 
Detailed information about the procedure 
 
Before the test 
You have to give your consent in writing prior to the test.  
There are no specific prior preparations or precautions for this test. 
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The day of the test 
The actual test takes only about 10 to 15 minutes. However, make arrangements to 
stay for 2-3hours from the time you arrive to the time you leave. Please arrive at MRI 
room 3 one hour prior to the scheduled test time. You will be asked to change into a 
hospital gown and remove all jewellery, dentures and hearing aids. 
 
During the test 
The test takes only about 10 to 15 minutes. You will be asked to lie down on a table 
that goes into the MRI scanner and connected to a machine that monitors your heart 
beat. Once the test starts, you will hear various sounds as the machine takes pictures.  
We will also prompt you with instructions. For example, we may ask you to hold your 
breath for 8 to 10 seconds at a time. It is important that you stay as still as possible 
because movements can create glitches in the pictures. 
 
After the test 
You may resume your normal activity immediately after the test. 
The test results will be sent to the doctor who is treating you in OPD by the following 
day. You will need to contact your treating doctor to discuss the results of your test. 
Keep any scheduled follow-up appointments with your primary doctor. 
 
For any querries, kindly contact Dr. Paul Deepak S., PG Registrar, department of 
Radiology, CMC, Vellore. 
Mobile - 9551555313 
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Informed Consent Form for Subjects 
 
Study Title: Role of cardiac MRI in Pulmonary Hypertension 
 
Study Number: ____________ 
 
Subject’s Initials: __________________  
 
Subject’s Name: _________________________________________ 
 
Date of Birth / Age: ___________________________ 
 
  (Subject) 
 
(i)  I confirm that I have read and understood the information sheet dated 
____________ for the above study and have had the opportunity to ask 
questions.   [  ] 
 
(ii)  I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care or 
legal rights being affected. [  ] 
 
(iii)  I understand that the Sponsor of the clinical trial, others working on the 
Sponsor’s behalf, the Ethics Committee and the regulatory authorities will not 
need my permission to look at my health records both in respect of the current 
study and any further research that may be conducted in relation to it, even if I 
withdraw from the trial. I agree to this access. However, I understand that my 
identity will not be revealed in any information released to third parties or 
published. [  ] 
 
(iv)  I agree not to restrict the use of any data or results that arise from this study 
provided such a use is only for scientific purpose(s). [  ] 
 
(v)  I agree to take part in the above study. [  ] 
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Signature (or Thumb impression) of the Subject/Legally Acceptable  
 
Date: _____/_____/______ 
 
Signatory’s Name: _________________________________         Signature:  
 
 
Or 
 
 
 
 
 
 
 
 
 
Representative: _________________ 
 
Date: _____/_____/______ 
 
Signatory’s Name: _________________________________ 
 
 
Signature of the Investigator: ________________________ 
 
Date: _____/_____/______ 
 
Study Investigator’s Name:Dr. Paul Deepak S, PG Registrar in Radiodiology, CMC, 
Vellore 
 
 
Signature (or) thumb impression of the Witness: ___________________________ 
 
Date: _____/_____/_______ 
 
Name and Address of the Witness: ______________________________ 
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Hindi patient information sheet and consent form 
 
 
                
 
           :                                     ए .आ .ऐ.           
              आ     स              स  आ                            
           स                    स       ईस                आ       
  ई               आ     स      ईस                        स स        
  , औ  आ          स      स आ             स   स       
 
इस              
       ए .आ .ऐ ए  स              श     श       ई               
      औ                                                ईस     स    
                       आ           आ                        
 
       ए .आ .ऐ       ?  
       ई           सस                                  ईस          
              श                             स           श           
                     स      स                                   
 
    इसस   स                 ?  
 सस            स                             
 
       इस              स        ?  
          स            ई   स                    
 
    आ                                     ?  
 स      स                 स                श            ,    
आ         स                                    , आ         स       
          स       स     उ                    स      स      , औ    
आ                       स        
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    आ  इस      स               स   स     ?  
 स      स         , आ   स      स                      स   स      
 स स आ      ई      स                 
 
                      
 
           :  
- आ    स                          
- एस               ई   श                          
 
          :  
-  स                       १० स १५                      
-             स   स ए            आ  ए  आ  ई     ३        
- आ                              
- स          ई        आ                  
 
            :  
- आ    ए  आ  ई                    स       आ                       
            ए  आ  ई              आ                    आ   स  ई 
      
- आ            स   ए        ए   ,   स    आ     ८ स १० स             
स     स                      
-  स              आ                          
 
          :  
- एस            आ       आ                     स      
-                  आ               स            
- आ  आ          स        स                                       स   
   
  स                                     स                       
(955155313)    email:pauldchristian@gmail.com 
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           :          इ                          ए  आ  ऐ     
      
 
      स   : 
 
              : 
 
                          ): 
 
          :  
 
                                               
_____________________________ 
 
ए                                       स                      
          ,  
 
       स                          
 
       स            स                                      औ  
       स      उ      
 
औ                                           एस            
   स        ए       
 
  औ   सस              ई  स           
 
  स                           औ  स             स        
स           उ             
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                                       औ  उस                
    स            
 
  स          स                         ई                 
 
  स                       स    स                              
    स            ए   
 
        स                   ए स            
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Telugu patient information sheet and consent form 
 
               : 
 
      :                           MRI     . 
             ఈ                                            . 
                                                       . ఈ    
                      ,                          . 
 
ఈ                  : 
        MRI                                                 
                                   .  ఈ                         
                    .                                         
                       . 
 
     MRI          ? 
        MRI                                                 
                                   . MRI                    . 
                          .                            .        
                                                   
           . 
 
ఈ     వ                ? 
ఈ                                        . 
 
    : 
ఈ                                  ,                        
               : 
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 ఈ                                                                     
             .                                . 
 
                   : 
                                                 . ఈ     
                                         . 
 
             : 
                        ఒ            MRI            3         .   
                      15 10                .    ఒ            
           ,           ,                              .      
    15 10                    .           2          
             . 
 
                 : 
    15 10                    .    MRI                     
        .                        ఒ                .     
                                    .                  .  
                    .        ,    ఒ         8-10        
                    . 
 
         : 
                                            .                  
   OPD                                   .                          
           .  
 
              ,                     ,            ,       , CMC 
                 .     – 9551555313. 
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               : 
      /         (          ): 
 
I_________________________________,       /        
_____________________________ 
           / ఈ                                                   
                                          . [ ] 
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                                           [ ]  
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              ఈ                                     [ ] 
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     : 
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       : 
            : 
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